Organic consequences of ileal transposition in rats with diet-induced obesity by Lucas P. F. F. Leal et al.
 
 
UNIVERSIDADE FEDERAL DE SÃO PAULO 
(FEDERAL UNIVERSITY OF SÃO PAULO) 
ESCOLA PAULISTA DE MEDICINA 
 
(SCHOOL OF MEDICINE) 
 
UNIFESP - EPM 
 
GRADUATE PROGRAM IN TRANSLATIONAL MEDICINE 
 
 
Coordinator: Prof. Dr. José Alberto Neder  
 
Ph.D. Research Project 
 
Lucas Pedroso Fernandes Ferreira Leal 
Co-Workers 
 
Gilmara Silva Aguiar Yamaguchi, Wellington Cardia, Bianca 
Marigliani, Karina Ferreira Neves, Paolo Henrique Barbanogo 
Lourenço, Marcelo Casciato Carlini, Joao Luiz Cansanção 
Azevedo, Otávio Cansanção Azevedo, Glícia Cansanção 
Azevedo, Gustavo Peixoto Soares Miguel, Gui Mi Ko 
 
 
Organic consequences of ileal transposition 
in rats with diet-induced obesity. 
 
Advisor: 
 
Prof. Dr. João Luiz Moreira Coutinho Azevedo 
 
 
Co-Advisors: 
 
Dra. Dr. Valderez Valero - Molecular Biology 
 
Prof. Dr. Ismael Dale Cotrim Guerreiro da Silva 
 
Prof. Dr. Anthony Gagliardi Ri Toledo - Endocrinology 
 
Dra. Dr. Maria Teresa de Seixas Alves - Pathology 
 
SÃO PAULO, BRAZIL - 2011
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
12
2.
1 
: P
os
te
d 
19
 J
ul
 2
01
1
ABSTRACT 
 
 
INTRODUCTION: The clinical management of metabolic syndrome - especially 
diabetes mellitus type 2 - is notoriously complex due to the progressive nature of this 
disease. At present, there is a need for a surgical procedure that is effective for the 
treatment of diabetes mellitus type 2, even in non-obese individuals. The isolated ileal 
transposition theory could lead to an effective alternative therapy. This intervention has 
not yet been performed in humans, and there are no reports of its use in an experimental 
model of diet-induced metabolic syndrome. 
 OBJECTIVES: The objective of this study is to evaluate the physiological effects of 
ileal transposition in rats with diet-induced metabolic syndrome. The effects of this 
procedure on glucose and lipid metabolism will be assessed.  
METHODS: Forty 12-week-old male rats (albino Rattus norvegicus, Wistar, 2BAW, 
heterogeneous) will be divided into four groups of 10 animals each: the ileal 
transposition group (TG) comprising animals on a hypercaloric-hyperlipidic diet; the 
sham group (SG) containing animals that receive the same diet and undergo the sham 
surgery; control group 1 (CG1), which will receive a hypercaloric-hyperlipidic diet and 
will not undergo surgery; and control group 2 (CG2), which will consume standard feed 
and will not undergo surgery. The surgeries will be performed in 20-week-old animals. 
Blood samples for laboratory testing will be collected from 12-week-old animals on the 
day of surgery and after eight postoperative weeks, following determination of the 
weights of the animals and the administration of anesthesia. The levels of serum 
glucose, insulin, triglycerides, total cholesterol and fractions, glucagon-like peptide-1, 
C-peptide and glycated hemoglobin will be assessed in all of the animals. The insulin 
tolerance test will be performed using PRISMA software, and insulin resistance will be 
calculated by the HOMA-IR indirect test. On specific days, two 20-week-old rats will 
be separated and randomly distributed in TG and SG. These animals will be followed 
until the eighth postoperative week. Subsequently, they will be euthanized, and the 
retroperitoneal and periepididymal fat deposits will be collected and weighed using a 
precision scale. In addition, the pancreas, liver and intestinal segments will be sent for 
pathological and immunohistochemical studies. 
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 1. INTRODUCTION 
 
 
In recent decades, the world‟s population has experienced a significant 
increase in the prevalence of obesity.
1
 At the transition of the millennium, 
approximately two thirds of adults in developed countries were obese, and nearly 5% of 
them suffered from morbid obesity.
2
 Morbid obesity predisposes patients to 
comorbidities that affect almost every organic system,
3
 and the association of obesity 
with insulin resistance (IR), systemic hypertension (HBP), dyslipidemia and diabetes 
mellitus type 2 (DM2) results in metabolic syndrome (MS), which represents an 
important risk factor for the development of cardiovascular disease.
4
 In 1998, the World 
Health Organization (WHO) established that MS is characterized by the association of 
IR or DM2 with two or more of the following criteria: (1) a blood pressure (BP) greater 
than or equal to 160/90 mmHg, (2) hyperlipidemia, defined as triglyceride levels above 
150 mg/dL and/or HDL cholesterol below 35 mg/dL in men and below 39 mg/dL in 
women, (3) central obesity with a waist/hip ratio of greater than 0.9 in men and greater 
than 0.85 in women and/or a BMI greater than 30 kg/m
2
 (4) and microalbuminuria of at 
least 20 mg/min or an albumin/creatinine ratio greater than 20 mg/g.
4
 Furthermore, 
these individuals often present cardiovascular disease, hypoventilation syndrome, 
asthma, sleep apnea, stroke, pseudotumor cerebri, arthropathies, several types of cancer, 
urinary incontinence, cholecystolithiasis, gastroesophageal reflux disease and 
depression.
4-6
 
 
Obesity results in a shortened life span.
7
 This reduction is approximately 12 
years in the morbidly obese in comparison to individuals with a normal weight and is 
directly proportional to increases in the body mass index (BMI).
8
 In the near future, 
morbid obesity will replace smoking as the leading cause of death in developed 
countries.
9
 Currently, in the United States alone, there are more than nine million 
morbidly obese patients who require assistance.
2
 However, the conservative treatment 
of morbid obesity with changes in diet and exercise, lifestyle modifications and 
medication only very rarely result in adequate levels of weight loss that are 
maintained.
10
 In fact, four long-term   studies   investigating   the   conservative   
treatment   of   obesity demonstrated  a  mean  weight  loss  of  only  4%.  A   
prospective  controlled study showed that conservative treatment over ten years resulted 
in an increased body weight of approximately 1.6% compared to a weight loss of 13.2% 
with the adjustable gastric band and 35% with gastroplasty reduction and gastrojejunal 
derivation.
15
 
 
Since the advent of minimally invasive surgery, there has been a 
considerable increase in gastrointestinal procedures that result in significant and 
lasting weight losses with low complication rates.
16-18
 Unlike the conservative 
approach,
19
 bariatric surgery determines the improvement or resolution of obesity-
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associated diseases in 70% to 100% of patients.
18
 In addition, the mortality rates in 
morbidly obese patients are significantly reduced following bariatric surgery in 
comparison to those determined in groups of obese patients undergoing medical 
treatment.
20,21
 Therefore, bariatric surgery is clearly the most effective treatment for 
morbid obesity; it promotes a significant and sustained weight loss, improves or 
resolves associated comorbidities and prolongs the life expectancy of patients.
22
 
 
The gold standard surgical treatment
23
 for the treatment of morbid obesity is 
the vertical banded gastroplasty with the gastrojejunal shunt using the Roux-en-Y 
technique (Fobi-Capella modified surgery
24,25
) because it achieves the goals of lasting 
weight loss and the control of comorbidities.
16
 The weight loss is usually attributed to a 
decline in the gastric pouch volume together with intestinal malabsorption. In turn, the 
control of comorbidities after Roux-en-Y gastroduodenal bypass - especially those 
resulting from glucose metabolism disorders - are generally attributed to an actual 
decrease in body mass. Nevertheless, endocrine effects potentially control blood 
glucose and promote early satiety following the Fobi-Capella procedure, even before 
any significant weight loss.
26
 
 
Additionally, substances that are secreted by the intestine directly into the 
bloodstream are increased in the peripheral blood following gastroduodenal bypass, 
such as glucagon-like peptide 1 (GLP-1) and peptide YY (PYY). These proteins can 
stimulate insulin production by pancreatic beta cells, facilitate the action of this 
hormone in the transport of glucose into cells and affect the hypothalamus to induce 
satiety.
27
 Moreover, Fobi-Capella surgery drastically reduces the levels of the 
orexigenic hormone ghrelin, which contributes significantly to the observed reduction 
of body weight.
28
 The levels of ghrelin decrease because the hormone-producing gastric 
areas (the gastric fundus and the greater curvature) do not receive a food stimulus due to 
their exclusion from the digestive tract.
28
 GLP-1 and the PYY increase in response to 
the Roux-en-Y gastrojejunal bypass-induced stimulation of L cells, which produce these 
hormones, and quickly and poorly digested food is observed in the most distal regions 
of the small intestine.
29
 Thus, the reductive vertical banded gastroplasty and the Roux-
en-Y gastrojejunal bypass (Fobi-Capella surgery) constitute successful metabolic 
interventions. 
 
Moreover, the generation of other surgical settings for the digestive tract has 
been recommended to trigger the appropriate metabolic response to the challenges 
associated with the surgical treatment of obesity. Thus, diverse surgical techniques are 
currently being evaluated. Research is also directed toward a surgical cure of 
comorbidities that are caused by the presence of excess fat. The issue is important 
because obesity is a condition that demonstrates an increasing incidence and 
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prevalence,
30
 a universal
31
 distribution, no discrimination of age groups and ethnicities 
and serious consequences to the health of patients due to its association with numerous 
comorbidities.
32
 Obesity is also associated with significant financial implications for the 
world economy.
33
 
 
Obesity appears to be an important issue among children and adolescents. 
The growing obesity pandemic has increasingly affected this population, and it can 
shorten their lives by up to 20 years.
34
 
 
Insulin resistance and diabetes mellitus are conditions that are commonly 
related to obesity. However, these conditions do not only affect the obese population, 
because there is an increasing incidence of type 2 diabetes among individuals with a 
body mass index (BMI) that is in the eutrophic and overweight ranges.
35,36
 Insulin 
resistance is known to be the primary cause of cardiovascular disease in these 
individuals.
37
 
 
The etiology of insulin resistance in obesity may be due to genetic factors. It 
has been postulated that natural selection will promote the survival of individuals who 
carry the "economy" energy gene, as such individuals will be endowed with a greater 
ability to store calories in fat tissue; this phenomenon would result in a clear survival 
advantage during periods of food scarcity, especially in our ancestral environment.
38-41
 
However, although modern individuals are equipped with genetic programming that is 
suitable for survival under any type of calorie restriction, some individuals have a 
greater number of these energy-saving economical genes in comparison to others, and 
therefore, they are more likely to develop obesity in response to a high calorie diet. 
Overfeeding combined with the sedentary lifestyle imposed by modern life causes the 
genetically predisposed to accumulate fat in central deposits in the body. This fat, which 
is known as visceral fat, is directly related to the development of insulin resistance and 
potentially to diabetes mellitus.
42
 
 
The quality of the diet also has an important influence on the development 
of insulin resistance.
43
 These factors modulate the insulin receptor or its signaling 
pathways, increase cytokine production by adipose tissue and alter the gastrointestinal 
production of enterohormones that are related to the hunger/satiety dichotomy and to 
carbohydrate metabolism.
44-46
 Mitochondrial dysfunction has also been proposed to be a 
primary cause of insulin resistance
47,48
 and the intracellular accumulation of fat.
49
 
 
However, in addition to functioning solely as a storage compartment, 
adipose tissue is also currently considered an endocrine organ that secretes molecules 
that are protective against the development of type 2 diabetes mellitus, such as 
adiponectine.
50
 Adipocytes also produce factors that trigger inflammatory phenomena 
responsible for a large number of diseases that are associated with obesity and insulin 
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resistance.
51-54
 
 
Within this multi-faceted and intensely imbricated range of factors that are 
involved in the genesis of obesity and its associated diseases (especially in the most 
important of them with respect to glucose metabolism disorders), the most prominent 
hormones, i.e., glucagon-like peptide-1 (GLP-1), are those produced by the digestive 
tract and, more specifically, those produced by L cells located in the small and large 
intestines and concentrated more densely in the terminal ileum.
55
 GLP-1 is secreted by 
neuroendocrine intestinal L cells in response to the direct stimulation generated by 
nutrients endowed with an incretin effect.
56
 
 
Incretins are hormones that are secreted in the gastrointestinal tract and enter 
the bloodstream in response to the intake of certain nutrients. This process results in an 
increase in insulin production and thus a rise in glucose uptake. GLP-1 has some well 
defined functions such as the following: stimulation of glucose-dependent insulin 
secretion; elevated transcription of the insulin gene, which increases the biosynthesis of 
this hormone; neogenesis and proliferation induction in beta cells in the islets of 
Langerhans; inhibition of beta cell apoptosis; increased phenotypic expression of 
differentiated beta cells; stimulation of somatostatin production; reduction of glucagon 
production.
57,58
 
Diabetes mellitus type 2 (DM2) is an epidemic that affects over 150 million 
people worldwide. This number is expected to double in the first decades of the third 
millenium.
59
 The therapeutic approach to DM2 and insulin resistance includes a wide 
variety of options, such as a multidisciplinary medical treatment aimed at weight loss, 
pharmacological options and bariatric and metabolic surgical techniques. The 
effectiveness of these techniques in controlling DM2 is well known, even over long-
term durations.
60
 Interestingly, bariatric interventions have also been shown to be 
effective for the treatment of type 1 diabetes by improving the therapeutic control of 
blood glucose.
61
 
 
In contrast, the maintenance of glycemic control in obese diabetics by 
conservative measures remains a challenge. Diets that require a high caloric restriction 
and multidisciplinary clinical programs for weight loss have rarely demonstrated 
benefits in medium- and long-term studies. In addition, antidiabetic drugs and the long-
term efficacy of insulin therapy are associated with limitations and side effects in 
DM2.
62,63
 In this context, bariatric and metabolic surgery is presented as a valid 
alternative for the treatment of obesity and its comorbidities, including DM2.
64,65
 
 
The evolution of motility studies of the digestive tract and the 
characterization of neurohormones (neurogastroenterology) have resulted in a better 
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understanding of the features of gastrointestinal physiology. Thus, bariatric surgical 
methods have evolved to the current concept of mixed procedures, which also address, 
in addition to the features of restriction and malabsorption, the neurohormonal and 
metabolic factors associated with such procedures. Baroendocrine surgery and 
metabolic surgery are used increasingly, especially for the treatment of diabetes mellitus 
type 2.
66,67
 
 
In fact, the "mixed" bariatric surgical methods comprise a more effective 
treatment for patients with morbid obesity; they demonstrate greater safety, sustained 
long-term weight loss and significant improvements in the associated comorbidities.
68
 A 
number of studies have shown that there is na increased release of GLP-1 and better 
glycemic control following a Roux-en-Y gastric bypass, even before the advent of 
significant weight loss. These findings demonstrate that the control of diabetes mellitus 
may be related to hormonal effects that are secondary to the surgical technique 
performed.
69,70
 
 
Although they provide greater weight loss that is sustained for longer 
periods, mixed techniques such as the Fobi-Capella procedure have disadvantages, 
especially over long durations, including dumping syndrome,
71
 internal hernias,
72
 
anastomosis stenosis,
73
 gastrogastric and enteroenteric fistulas,
74,75
 peptic ulcers,
76
 
diarrhea, hypoproteinemia, hypocalcemia and difficulty associated with endoscopic 
access to areas outside the digestive tube.
77-79
 
 
With the goal of avoiding the complications associated with the Fobi-
Capella procedure, vertical gastrectomy emerged. This procedure was previously the 
first part of a more complex mixed operation called the duodenal switch,
80
 and it 
involves the removal of the greater curvature and gastric fundus and a consequent 
reduction of ghrelin production.
81-82
 Vertical gastrectomy is an emergent restrictive 
bariatric surgery;
83,84
 it causes satiety and can be used as an initial stage in a two-stage 
operation for high-risk surgical patients,
85-87
 or as an isolated and final surgery.
88
 
 
Vertical gastrectomy alone has demonstrated satisfactory results in weight 
loss,
89
 glycemic control
90
 and early satiety, even in long-term assessments.
91
 The 
achieved postoperative glycemic control may be due to the arrival at the distal ileum of 
food that is not fully digested. This phenomenon depends on the increased speed of 
gastric emptying after surgery and results in an increase in GLP1 secretion by L 
cells.
92,93
 
 
Recent studies have shown that vertical gastrectomy as an isolated and 
definite bariatric surgery is as effective as the Fobi-Capella procedure for the control of 
comorbidities; in addition, it provides the potential to avoid some of the associated 
complications.
94-97
 Although the surgical procedure is simpler, research investigating 
humans who were undergoing vertical gastrectomy alone demonstrated the presence of 
limitations
98
 and complications.
99,100
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Studies continue to be developed with the objective of developing simpler 
and effective surgical therapies for metabolic diseases that are associated with 
overweight and obese individuals, especially DM2. In this scenario, it has been 
postulated that anti-incretin factors may be secreted into the proximal small intestine 
and that these factors would no longer be produced in the absence of that intestinal 
segment. The absence of the alleged "anti-incretin" in circulation would enhance the 
action of incretins and thus improve DM2.
101-105
 
 
Several authors claim to have demonstrated that derivation of the digestive 
transit to exclude a short segment of the proximal small intestine alone provides an 
improvement in diabetes mellitus type 2, irrespective of the effects of restricted food 
intake, loss of body weight, possible malabsorption of foods or the arrival of a smaller 
amount of digested food in the distal small intestine. Based on their results, these 
authors advocate surgery with duodenal exclusion as a valid alternative for the 
treatment of diabetes mellitus type 2. Moreover, they argue that other unknown factors 
or substances secreted by the proximal intestine may contribute to the etiopathogenesis 
of diabetes mellitus type 2.
101-105 
More recently, promising results have been reported with respect to 
techniques that combine vertical gastrectomy and interposition of the distal ileum in the 
proximal jejunum in humans. This type of surgical procedure may induce early satiety 
together with improved glucose metabolism and result in weight loss over short and 
medium durations. In non-obese diabetic patients, this surgical technique has been 
shown to be effective in controlling diabetes mellitus type 2.
106-111
 
 
Interestingly, in the antidiabetic surgical interventions proposed by that 
team,
106-111
 vertical gastrectomy was one of the prominent surgical techniques 
employed. Note that vertical gastrectomy is a restrictive (based on the marked reduction 
of the gastric reservoir capacity) metabolic procedure (based on the reduction of 
circulating levels of the orexigenic hormone ghrelin, which is produced by the fundus 
and greater gastric curvature)
82,91
 that primarily aims to achieve weight loss. In this 
scenario, the following question arises: what is the purpose of conducting this operative 
step (vertical gastrectomy) in patients who do not require weight loss? One can infer 
that the metabolic benefits obtained by such procedures are almost exclusively due to 
ileal interposition. Note that the increased speed of intestinal transit caused by vertical 
gastrectomy
92,93
 may contribute to the more rapid arrival of undigested food in the 
region of ileal segment interposition and thus contribute to the production of GLP-1 by 
L cells in the ileum. Nevertheless, the isolated ileal interposition has proven to be 
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effective in correcting dysmetabolism in several animal studies.
112, 113
 
 
It should be noted that an evaluation of surgical modalities in the context of 
metabolic and bariatric surgeries that involve ileal transposition alone has not yet been 
performed in humans. However, animal studies have demonstrated that the interposition 
of a segment of the distal ileum in the proximal jejunum involves an increase in the 
synthesis and release of GLP-1.
114
 This phenomenon can be attributed to a greater 
stimulation of the L cells located in the interposed segment of the ileum due to a greater 
amount of partially digested nutrients. The facilitated arrival of nutrients in this portion 
of the distal small intestine causes the release of GLP-1. GLP-1 in turn stimulates an 
increase in the production of insulin, which directly affects glucose metabolism.
115
 
GLP-1 levels increase in the plasma in response to food stimuli and have a satiating 
effect on the central nervous system,
116
 reduce the absorption of fat via the 
gastrointestinal tract
117
 and decrease gastric
118
 and intestinal
119
 motility. Finally, the 
most notable effect of GLP-1 is the promotion of a decrease in peripheral insulin 
resistance, a reduction of apoptosis in pancreatic β cells and an increase in the 
differentiation of primitive cells in pancreatic canaliculi into adult beta cells and an 
increase in their proliferation,
120,121
 which is known as "empty ileum syndrome".
122-124
 
 
GLP-1 is an incretin hormone that demonstrates a strong association with 
the antidiabetic effects of bariatric surgery. The stimulation of ileal L cells to cleave 
proglucagon and release GLP-1 appears to be the most effective means of obtaining the 
effect of incretin in diabetic patients undergoing bariatric surgery. Several techniques 
can achieve this effect, all of which are based on the hindgut theory. This theory is 
based on the knowledge that when the ileum is contacted by food that is incompletely 
digested, it corrects the deleterious effects of "empty distal bowel syndrome" that are 
caused by a lack of L cell stimulation to produce GLP-1. 
 
Stimulation of the ileum by undigested foods causes the release of intestinal 
hormones with actions that interfere positively in the control of obesity and its 
associated metabolic disturbances, especially in peripheral insulin resistance. The mere 
interposition of an ileal segment in more proximal segments of the small intestine 
provides results that better emphasize this hypothesis. A study of the interposed 
segment of the terminal ileum in the proximal jejunum in experimental animals that 
were subjected to a model of diet-induced obesity demonstrated significantly increased 
levels of GLP-1.
125
 Similarly, a clinical study of a surgical technique that places an ileal 
segment 50 cm distal to the Treitz angle showed the same endocrine stimulation and an 
improvement of diabetes.
111,126
 
 
Research demonstrating the ability of ileal food stimulation to release GLP-
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
12
2.
1 
: P
os
te
d 
19
 J
ul
 2
01
1
1 and cause an incretin effect is abundant in the literature. However, the histological 
studies investigating L cells were performed prior to the achievement of current 
scientific knowledge. These studies merely identify the location of these cells and 
indicate that they are capable of proglucagon cleavage and the release of products 
(GLP-1 and GLP-2).
127-129
 At present, these cells are considered to have a greater role in 
the surgical treatment of DM2, which seeks to elucidate therapeutic measures for DM2 
based on the effect of incretin. Therefore, a knowledge of the response of L cells to this 
effect seems to be an important step in that knowledge.
130
 
 
A large amount of research and information in humans are available in the 
biomedical literature. However, in comparison with clinical studies, studies involving 
experimental animals in metabolic and bariatric surgery are scarce. The use of 
experimental animals, especially rats, in models of obesity and metabolic syndrome 
appear to provide greater credibility to the conclusions obtained in comparison to 
healthy animals. Consequently, several experimental models have been utilized.
102,131-134
 
 
The diet-induced obesity animal model - in which obesity is achieved via 
modulation of the diet - appears to provide the best mimic of the human obese 
condition. Although no clear pattern is evident, in most cases, morbid obesity is caused 
by an increase of the relative amount of fat in the diet.
138-135
 Although the conclusions 
cannot be directly extrapolated to humans, experimental research in animals is relevant 
because euthanasia and the post-mortem examination of animals can be performed; of 
particular importance is the histopathology of the digestive tract. Although the profile 
for enterohormones after bariatric surgery together with the effects of incretin in 
humans is known, a direct correlation with the responses of intestinal L cells has not 
been described in this context. 
 
In addition to the "ileal brake" - a term used to characterize the reduced 
motility of the proximal gastrointestinal transit, which is associated with the 
enterohormone production
139-142
 secondary to ileal interposition surgery - studies have 
demonstrated the beneficial effects of this surgical technique in the structure of the 
pancreas, especially in diabetic and non-obese experimental animals.
113,115
 It has also 
been noted that in euglycemic rats, the ileal interposition improves glucose tolerance; 
however, the pancreas of these animals was not evaluated.
143
 
 
Diabetes mellitus type 2 is a progressive heterogeneous metabolic disease. 
The pathophysiological mechanisms associated with this disease involve two main 
effects: peripheral insulin resistance and a progressive dysfunction of pancreatic beta 
cells.
144,145
 These effects invariably arise when the islets are no longer capable of 
maintaining a hyperinsulinemia level that is sufficient to counteract the peripheral tissue 
resistance. Thus, the treatment is initially directed toward a reduction of weight and 
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consequently insulin resistance, thus improving glucose tolerance. 
 
Over the years, diabetes has undergone intermediate stages, where both 
effects can coexist, indicating association with insulin-sensitizing drugs, which are 
insulin secretagogue drugs. As the deficiency increases, the therapeutic combinations of 
oral agents may cease to be effective in the control of hyperglycemia, and therefore, 
insulin administration is needed to optimize the 
treatment.144,146-148 
 
In a given patient, it is essential to characterize his or her degree of insulin 
resistance according to the observed clinical condition. This strategy will determine the 
therapeutic orientation. None of the current therapeutics has a significant effect on the 
progression of this disease.
149
 
 
In type 2 diabetic subjects, in whom obesity and insulin resistance are 
present in more than 80% of cases, the treatment should initially be based on a dramatic 
lifestyle change. It is addressed primarily to the dietary adequacy, with low-calorie diet 
and implementation of regular physical activity,
150
 although with a tendency to crumble. 
However, when behavioral measures are not sufficient to achieve or maintain adequate 
glycemic patterns together with weight loss - as observed in most patients due mainly to 
a lack of compliance with these lifestyle changes and disease evolution - oral 
antidiabetic agents should also be utilized.
151
 
 
At present, different classes of drugs with different mechanisms of action 
are available, and these drugs can be used alone or in various combination therapies.
150
 
Many patients do not achieve adequate glycemic control with the use of a single drug 
and require long-term combinations of two or more oral agents,
151-153
 sometimes as a 
prelude to insulin therapy. 
 
In recent years, with the goal of improving patient adherence to drug 
combinations, preparations have appeared on the market that contain two components in 
a single tablet. However, over the years, traditional treatments with oral agents are no 
longer effective, and consequently, glucose levels increase and metabolic control is lost. 
Thus, depending on the disease evolution, individuals will require the administration of 
insulin.
148
 
 
The combined regimen of insulin together with oral agents may also become 
insufficient over time, as evidenced by an increase in blood glucose levels by self-
monitoring and a progressive increase in the levels of glycated hemoglobin. 
Consequently, larger and more frequent daily doses of insulin are required. Finally, 
when it is no longer possible to use combined formulations of oral agents and insulin, 
full insulinization is indicated. Nevertheless, insulin is the only effective therapeutic 
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alternative when conservative measures and oral antidiabetic agents are no longer 
sufficient for metabolic control.
144,146,154
 
 
The intensification of insulin therapy in the treatment of type 2 diabetes is 
the most appropriate strategy to achieve normoglycemia and to reduce disease 
complications together with early, thorough, persistent and effective glycemic 
control.
144,155-157
 Although patients undergoing intensive treatment are unable to achieve 
a normalization of glycated hemoglobin levels, they present a significant reduction of 
the risk for the onset or progression of chronic complications and late complications in 
diabetes (micro and macrovascular complications), which are an important cause of 
morbidity and mortality in the affected population.
144,155,156
 
 
Thus, type 2 diabetes is a multifaceted condition that requires the integrated 
and individualized care of each patient,
150
 and such care can be challenging 
challenge.
158
 Patients often present poor blood glucose control despite the associated 
therapeutic measures.
149,158
 
 
The glycemic control of an individual with type 2 diabetes is considered 
optimum when his or her glucose values are similar the level detected in an individual 
without diabetes,
159
 with respect to the prevention of complications.
144
 Therefore, the 
achievement of optimal levels of glycemic control remains a major challenge in clinical 
practice; only a small portion of people with diabetes attain the therapeutic goals.
157,159
 
 
The limitations of most of the available therapeutic measures have 
prevented the achievement of this objective
159
. This observation may be explained by 
poor adherence to diet, also not so effective, and insufficient initiatives for weight loss, 
added to the limited efficacy of therapeutic agents associated with excessive adverse 
events or delay on the onset of insulin therapy and the poor acceptance of a daily 
regimen of multiple injections by the patient.
157,160
 
 
It is well known that most individuals will not sustain an adequate level of 
glycemic control based on behavioral measures or oral monotherapy.
151
 In addition, 
even if traditional oral therapies are usually effective in reducing hyperglycemia, they 
do not prevent or impede the progression of the disease, and thus, many patients require 
the administration of insulin.
148
 Other individuals may also have allergies or 
contraindications to the medications, and they may not adhere or be resistant to 
continuity of the treatment in the presence of undesirable side effects such as weight 
gain and hypoglycemia, which are associated with many conventional therapies. In 
addition, individuals may present skin reactions, gastrointestinal disorders, hematologic 
reactions, acute coronary events, visual changes and metabolic diseases, which limits 
the use of these therapies.
147-149,152,158,161
 
 
Most antidiabetic medications, including sulfonylurea, thiazolidinediones 
and insulin, improve glycemic control but do not always correct the associated 
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metabolic disorders and are associated with an increase in body weight (as occurs with 
insulin treatment) by stimulating the appetite; this phenomenon generates 
concern.
147,161,162
 Sulfonylurea has been shown to accelerate apoptosis in beta cells, 
which results in a decline of linear functions and a decrease in the mass of the human 
pancreas.
145
 Concerning thiazolidinediones, the associated weight gain is promoted by 
volume expansion and edema, which can lead to heart failure in susceptible individuals 
or aggravate a pre-existing condition. Thus, thiazolidinediones may cause or exacerbate 
congestive heart failure and even ischemic cardiac events, mitigating the risks 
associated with the increase in body fat.
151,152,161
 Recent data also suggest that 
thiazolidinediones can reduce mineral bone density.
151
 Thus, the therapeutic strategy 
must consider the effects on the associated comorbidities and associated costs, in 
addition to the decrease in glycated hemoglobin, the tolerability and the non-glycemic 
effects of antidiabetic agents.
151,154
 
 
In addition to the progressive nature of the disease itself, inadequate 
glycemic control is also caused by delays in the initiation of treatment with oral 
antidiabetics and insulin and a failure to implement the early intensification of insulin 
therapy in patients who are not achieving their glycemic goals.
148,155
 
 
There are barriers for both patients and doctors who undertake the initiation 
and intensification of insulin therapy; these barriers correlate with poor individual 
motivation, a lack of familiarity with application, the need for frequent insulin 
injections, fear that the injection will be painful and difficult to administer and concerns 
regarding hypoglycemia and weight gain.
155,160,163
 Consequently, an inappropriate delay 
in the initiation of early insulin therapy prevents the achievement of the recommended 
glucose levels and the maintenance of adequate glycemic control.
146,154,160
 
 
To achieve a successful insulin therapy, the patient must be adequately 
informed and motivated by the participation and support of a multidisciplinary team. At 
present, several insulin preparations are available for the treatment of diabetes, 
including different pre-mixes and cartridge preparations that are applied via pen 
injectors. These techniques can increase the complexity of the treatment of diabetes. 
The patient should be instructed with respect to the various presentations, forms, routes 
and sites of drug application. The storage and care of insulin and the importance of 
monitoring blood glucose should also be explained. Furthermore, the need for other 
lifestyle changes, such as a proper diet and physical activity level, must be emphasized. 
The risk for the development of hypoglycemia should also be explained to the patients 
and their families, together with the measures necessary to prevent and reverse this 
condition. 
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Thus, the intensive insulin treatment scheme requires a higher level of 
socio-economic and cultural development in the patient, a high level of compliance and 
the ability to learn; the patient will be monitoring the treatment and determining the 
insulin rates, the presence of hypoglycemia and the prevention of acute complications. 
The required amount of knowledge is rather large, and the patients must be aware of the 
availability of resources to implement the treatment protocol. In addition, both the 
patient and the entire multi-professional medical team should be involved in the 
treatment. 
 
Thus, there is a clear need for new, more aggressive antidiabetic therapeutic 
options, which could be combined with the existing pharmacological agents to preserve 
the functions of beta cells and halt the progression of diabetes mellitus type 2.
147
 None 
of the mentioned available therapies for diabetes mellitus have been shown to preserve 
the functions of pancreatic beta cells over time. The limitations of this treatment 
demonstrate the importance of discovering new resources that offer greater efficiency, 
durability, convenience, safety and tolerability to achieve the goals of early adequate 
glycemic control and the prevention or delay of the need for additional measures.
145
 
More aggressive options are therefore required based on the pathogenesis of this 
disease, and such options should include a greater control of both fasting and 
postprandial glucose.
154
 
 
Incretin-based therapies such as GLP-1 receptor agonists administrated 
subcutaneously and DPP-4 inhibitors (dipeptidyl peptidase-4) administered orally offer 
a new, more current and interesting approach in the management of type 2 diabetes, and 
the development of new agents is currently underway.
145,149
 The two groups that are 
presently available have been demonstrated to be safe and effective in reducing blood 
glucose levels while also promoting a favorable effect on weight reduction and 
maintenance.
148,151,161,162
 Some studies have demonstrated the beneficial effects of these 
promising drugs on the lipid profile and blood pressure in patients.
145
 
 
Agonists of the GLP-1 receptor and inhibitors of DPP-4 both lead to the 
secretion of insulin and the suppression of glucose-dependent glucagon, with a 
consequent low risk for hypoglycemia when used alone or in combination therapies, 
excluding the concomitant use of sulfonylurea. Moreover, experimental studies have 
demonstrated a prolonged survival of pancreatic beta cells, with a delay in their 
dysfunction and a promotion of their regeneration. Theoretically, these phenomena 
permit a possible decrease in the progression of type 2 diabetes mellitus. These results 
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have not yet been verified in clinical studies.
145,148,149
 
 
However, despite the attractive features of these new agents, their high cost 
in comparison to first-line oral drugs and the lack of long-term data concerning their 
safety and clinical outcomes should be considered. There have been reports of nausea, 
headache and cases of acute pancreatitis, upper respiratory infection, depression, 
hypoglycemia and severe allergic skin reactions associated with the use of these drugs; 
some individuals also exhibit a modest reduction (approximately 1.0%) of glycated 
hemoglobin (HbA1C) levels in comparison to the levels detected in patients treated with 
insulin and older agents. The development of carcinomas in guinea pigs in response to 
new agents has not yet been confirmed in humans.
145,152,153
 
 
In addition to the new classes of antidiabetic medications, the development 
of insulin analogues and other non-invasive alternatives to the use of insulin are 
promising options for the management of diabetes mellitus type 2. 
146,163 
Such agents 
may assist in overcoming some of the challenges associated with this disease to achieve 
enhanced glycemic control, despite the difficulties associated with the natural disease 
progression and the loss of efficacy related to the use of long-term oral agents.
159
 
 
Novel basal insulin analogues, including pre-mixes such as lispro, aspart 
and glargine, represent a more physiological replacement to previous therapies because 
they provide greater freedom, flexibility and convenience with respect to the drug 
administration. Concerning the content of the diet, they provide a better quality of life 
compared to regular insulin formulations.
144,146,163
 Innovative formulations without the 
need for subcutaneous injections can overcome some of the shortcomings associated 
with typical insulin therapy and thereby facilitate the early use of insulin. These effects 
allow the achievement and continuance of long-term glycemic control, which enhances 
quality of life.
157
 Moreover, there is a clear need to include appropriate types of 
counseling with individual education in the modern therapies available for the clinical 
treatment of type 2 diabetes to overcome the known barriers related to insulin 
therapy.
154
 
                   The objectives of the treatment of diabetes mellitus type 2 are to improve 
the quality of life and prevent early mortality in patients through glycemic control, 
which minimizes the risk for microvascular effects; however, substantial benefits 
regarding macrovascular implications have not been demonstrated.
62,164-167
 
 
Meanwhile, the maintenance of adequate glycemic control in obese patients 
with type 2 diabetes using conservative techniques remains a real challenge. Diets that 
require a large calorie restriction and multidisciplinary clinical weight loss programs 
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have rarely demonstrated significant benefits over medium and long-term periods that 
extend beyond their own limitations and the side effects associated with antidiabetic 
agents and insulin therapy. To date, even intensive schemes for glycemic control that 
combine and optimize the institution of traditional agents have failed to achieve these 
therapeutic goals. In addition, the new oral agents and insulin analogues, which require 
further studies for validation, consider the individual needs and lifestyle of each patient. 
Thus, in addition to significant glycemic control, measures concerning the lifestyles of 
diabetic patients with respect to the reduction of obesity, hypertension, dyslipidemia and 
smoking must be considered to achieve the desired goals in the treatment of type 2 
diabetes.
62,145,154,168
 
 
In the therapeutic management of DM2 and insulin resistance, in addition to 
a wide variety of multidisciplinary clinical treatment options, which aim to achieve 
weight loss and glycemic control using pharmacological agents, bariatric and metabolic 
surgical techniques may be important in this treatment regime. It is well known that 
these surgical techniques can control type 2 diabetes, even over long-term periods.
169
 
The surgical treatment of patients with diabetes mellitus type 2, irrespective of obesity, 
must currently be considered as a valid alternative approach to the treatment of this 
disease. 
 
2. OBJECTIVES 
 
2.1 General 
 
To evaluate the physiological effects of ileal transposition in metabolic 
syndrome. 
 
2.2 Specific 
 
2.2.1.  To  investigate  the  morphological  and  functional  changes  that 
occur in intestinal L cells in a segment of the distal ileum interposed to the proximal 
jejunum in rats with diet-induced obesity. 
 
2.2.2. To study the structural changes in the small intestine of animals 
subjected to the transposition of a segment of the distal ileum to a proximal location in 
the digestive tract in rats with diet-induced obesity. 
 
2.2.3. To quantify and evaluate the morphology of endocrine cells in the 
pancreas after ileal transposition in rats with diet-induced obesity. 
 
2.2.4. To verify the changes in the metabolism of glucose and lipids in rats 
with diet-induced obesity that are submitted to ileal transposition. 
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3. BACKGROUND AND EXPECTED OUTCOMES 
 
 
The surgical intervention studied herein – the interposition of the ileal 
segment in the proximal jejunum - could become a valuable therapeutic approach for 
the control of diabetes mellitus type 2, even in non-obese individuals, because it does 
not affect the absorption of nutrients. The evaluated surgery is simple to execute, 
inexpensive, can be easily reversed and does not require removal of the digestive tube 
segment or result in food transit deviations. Thus, this technique avoids the incidence of 
malnutrition and other complications. 
 
However, there is the need to investigate the possibility that with a long-
term, constant exposure to high levels of digestive juices from the stomach, pancreas 
and liver and the constant contact between the transposed ileal mucosa and the 
incompletely digested food, the mucosa of the ileum will become "jejunized", i.e., it 
will present histological cell features, membrane structures of absorption and exocrine 
and endocrine secretion patterns similar to those associated with the jejunum. This 
potential "jejunization" of the ileum is of interest only with respect to exocrine and 
absorptive components (which cause no problems) or changes in the ileal endocrine 
pattern (a high density of GLP-1-producing L cells) toward that of the jejunum (a low 
density of these cells). This last circumstance will invalidate the efficiency of the 
proposed technique in the long term. It is noteworthy that if the present research is 
rejected, the theoretical possibility that the epithelium of the mucous membrane of the 
interposed ileal segment in the proximal jejunum acquires a jejunal phenotype - 
including in particular the low density of L cells typical of the proximal jejunum - 
would be the only theoretical obstacle to the achievement of ileal interposition in 
diabetic individuals. Thus, if the interposed ileum maintains a high density of L cells, 
the long-term action (mainly toward the endocrine pancreas) of the well studied 
beneficial trophic effects of GLP-1 will be guaranteed. 
 
Once such intervention has been studied in the context of translational 
medicine in animals, which demonstrate physiological characteristics that are very 
similar to those of humans, with respect to glucose metabolism and nutrition in general. 
The results of this study could be extrapolated to clinical scenarios. The relevance of 
this research lies in the benefits that the studied surgical intervention could provide to a 
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large population of diabetic patients, even non-obese patients that present substantial 
control and even remission of dysglycemia. 
 
The use of immunohistochemistry of the intestinal tissue is expected to 
demonstrate the preservation of the high density of L cells in the interposed ileum, 
despite the anticipated change in the mucosal epithelium with respect to exocrine 
secretion and absorption from the ileal to the jejunal pattern. This hypothesis is based on 
the knowledge that the differentiation of stem cells in the crypts toward L cells is not 
affected by epigenetic modifications. Researchers hope that the stem cells in the crypts 
of the fundus will continue to differentiate normally into L cells. These stimuli are 
known to induce the transformation of the ileal secretory exocrine and absorptive 
epithelial patterns in the mucosa of the jejunum; however, it remains unknown whether 
this "jejunization" also involves the transformation of the high density of L cells in the 
normal ileum to a low density of these cells in the transposed ileum. 
Immunohistochemistry of pancreatic tissue should demonstrate the preservation of the 
islets of Langerhans, insulin-producing cells and proliferating cells. Glucose intolerance 
and insulin resistance should diminish or disappear in the group undergoing ileal 
transposition. Some weight reduction in the absence of malnutrition should be observed 
in the animals undergoing ileal transposition, and no associated adverse effects are 
expected. 
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5. METHODS 
 
 
 
Experimental Model 
 
 
This research project was approuved by Experimental Research Ethics 
Committee of the Federal University of São Paulo - Escola Paulista de Medicina 
(Universidade Federal de São Paulo - UNIFESP/EPM). 
 
Sample 
 
The sample includes 40 male rats (Rattus norvegicus albinus, Wistar 
2BAW, heterogeneous) aged 12 weeks with a body weight ranging from 250 to 280 g. 
The animals will be supplied by the Laboratory of Animal Experiments at the 
Pharmacology and Molecular Biology Institute (Laboratório de Experimentação Animal 
do Instituto de Farmacologia e Biologia Molecular, Universidade Federal de São Paulo, 
Escola Paulista de Medicina (UNIFESP/EPM)), where they will be maintained 
throughout the experimental procedure. 
 
The animals will be housed in individual cages for 16 weeks with a 
controlled room temperature of 23 ± 2°C, a relative humidity of 55 ± 15% and an 
automatic timer (Kienzle) that provides 12 hours of alternating light and dark cycles 
(06:00/18:00). 
 
The animals will be randomly divided into four groups according to the 
chart below: 
- transposition group (TG) - animals submitted to ileal transposition, 10 animals that 
receive a hypercaloric-hyperlipidic diet;  
 
- sham group (SG) - animals submitted to the sham surgery, 10 animals that receive the 
same diet;  
 
- control group 1 (CG1) - animals that are not submitted to any surgical intervention 
but receive a hypercaloric-hyperlipidic diet;  
 
- control group 2 (CG2) - animals that are not submitted to any surgical intervention or 
a hypercaloric-hyperlipidic diet but receive only standard feed, 10 animals.  
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The surgeries will be performed in 20-week-old animals. All of the animals 
will be monitored until the 8
th
 postoperative (PO) week, i.e., the 28
th
 week of life, at 
which time they will be sacrificed. 
 
 
Experimental Procedures 
 
The experimental procedures will be performed in accordance with the 
guidelines of “Cuidados e Manejos de Animais de Laboratório,” Ed: Lapchick, 
Mattaraia, Ko; Atheneu, 2009, CDD 636.0885. 
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Diet 
 
The rats will be randomly allocated to the TG, SG and CG1 groups and 
maintained on a high calorie diet (DH) that is rich in lipids, pelletized and provided ad 
libitum with alternate cycles of four different types of food (1, 2, 3 and 4) for a period of 
16 weeks to stimulate food intake. The experimental diets will alternate every 24 hours, 
and the amount of food that has not been consumed will be measured. The consumption 
of these diets will promote obesity in animals, which will result in features that are 
commonly associated with human obesity, such as insulin resistance, hyperglycemia, 
hyperinsulinemia, dyslipidemia and hepatic steatosis. The animals in group CG2 will 
receive a standard diet. All of the groups will have unlimited access to water. 
 
The experimental diets 1, 2, 3 and 4, according to the specifications 
established by the Nutrient Requirements of the Laboratory Rat recommended by the 
National Academy of Sciences, will be industrially produced by Nuvital®, São Paulo - 
SP. These diets will consist of standard Nuvital® feed for rats, which contains protein 
and vitamin and mineral supplementation. The additional hyperenergetic ingredients 
included in the preparation of the experimental hypercaloric diets are (in grams per 
kilogram): 
 
 
- DH1 - Nuvital® standard feed, 355; roasted peanuts, 176; casein, 123; 
corn oil, 82; chocolate, 88; corn biscuit, 176; vitamins and minerals. 
 
 
- DH2 - Nuvital® standard feed, 439; roasted peanuts, 218; casein, 129; 
corn oil, 61; potato chips, 153; vitamins and minerals. 
 
 
- DH3 - Nuvital® standard feed, 371; roasted peanuts, 185; casein, 99; corn 
oil, 68; noodles, 185; grated cheese, 92; vitamins and minerals. 
 
 
- DH4 - Nuvital® standard feed, 359; roasted peanuts, 179; casein, 105; 
corn oil, 80; condensed milk, 161; wafer biscuit, 116; vitamins and minerals. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
12
2.
1 
: P
os
te
d 
19
 J
ul
 2
01
1
24 
 
 
The macronutrient composition of the standard and experimental 
hypercaloric-hyperlipidemic feeds, which were produced and analyzed by Nuvital®, 
São Paulo - SP, is shown in Table 1. 
 
 
 
 
Table 1 - Composition of standard and experimental diets. 
 
 
 
 
   Feeds   
      
Components Pattern DH1 DH2 DH3 DH4 
      
Protein (%) 26 27 28 28 26 
Carbohydrates (%) 54 43 36 33 43 
Fat (%) 3 20 23 24 20 
Others (%) 
†
 17 10 13 15 11 
Calories (kcal/g) 3.5 4.6 4.6 4.6 4.6 
 
† - vitamins, minerals, moisture, ash. 
 
 
 
 
 
 
Weight and Feed Intake Curves 
 
The animals will be weighed twice a week on pre-established days. 
Weighing will be performed at the start of the light period using an appropriate 
precision scale (Filizola BP-6), and the weight of each animal will be recorded in 
grams. 
 
Feed intake will be measured three times a week on pre-determined days by 
calculating the difference between the weights of the feed provided and that consumed 
in each cage. These results will be calculated in grams. 
 
Weight and feed intake curves will be generated for all of the groups 
throughout the experiment. 
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                  Fasting 
 
Animals in all of the groups will be offered only water during the six hours 
prior to the collection of blood for laboratory tests and surgical procedures. 
Blood Collection and Laboratory Tests 
 
Blood samples will be collected for laboratory testing from 12-week-old 
animals (W12), on the day of surgery (S20) and eight weeks after the surgery or at 28 
weeks of age (S28). For this procedure, the animals will be weighed and anesthetized. 
 
The blood collection on day zero (D0) will be performed to obtain the 
baseline parameters of each animal, whereas that performed on the day of surgery will 
determine changes in glucose metabolism that are secondary to the obesity induced by 
the hypercaloric-hyperlipidemic diets. The blood collection at eight weeks after surgery 
will be performed to evaluate changes in the same metabolic changes following the 
surgeries. 
 
One milliliter of blood will be collected into heparinized tubes by 
puncturing the tail vein of each animal, followed by centrifugation and subsequent 
storage at -20°C for the determination of blood parameters (LABTEST®), including 
glucose (GLU), triglycerides (TG), total cholesterol (COL) and the fractions of low-
density lipoprotein (LDL) and high-density lipoprotein (HDL); the levels of insulin 
(INS), glycated hemoglobin (HBG), C-peptide (CPT) and glucagon-like peptide-1 
(GLP1) will be evaluated by ELISA (Linco®). After 10 minutes of blood collection, the 
serum glucose level will be determined with reagent strips using a glucometer (Accu-
Chek Advantage Kit®) followed by the insulin tolerance test (ITT), for which a solution 
of regular insulin at a concentration of 1 U/kg body weight will be injected through the 
penile vein. Blood samples will then be collected to determine the levels of glucose. A 
lancet will be used to obtain a drop of blood from the tail of each animal at 4, 8, 12 and 
16 minutes after the injection of insulin. The results will be recorded for later analyses. 
 
Anesthesia, Weight Assessment and Antibiotic Prophylaxis 
 
Prior to anesthesia, all of the animals will be weighed using a precision scale 
(Filizola BP-6), and their weights will be recorded in grams. In 
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both groups TG and SG, general anesthesia will be induced with halothane to collect 
blood from the tail. Subsequently, a dissociative general anesthetic will be used to 
perform the insulin tolerance test and surgery: Zoletil 50® (tiletamine + zolazepam) at a 
dose of 20 mg/kg and fentanyl® at a dose of 0.025 mg/kg, collected in the same syringe 
and administered simultaneously via an intramuscular injection.
170
 
 
Each animal will be maintained under spontaneous ventilation during the 
procedures, and anesthesia will be monitored through regular evaluations (every 45 
minutes) of the auricular and interdigital reflexes, which should be abolished in 
anesthetized animals. If such reflexes are observed, complementary doses that comprise 
one third of the initial dose will be administered. After completion of the surgery, the 
total amount of anesthetic used will be recorded. 
 
The antibiotic prophylaxis will comprise an intramuscular injection of 50 mg/kg 
cefoxitin immediately after the surgical anesthesia. 
 
Operative Procedures 
 
On predetermined days, two 20-week-old (S20) rats will be distributed 
randomly into TG and SG. The aseptic and antiseptic techniques associated with 
Halsted‟s principle will be performed using sterile micro-surgical instruments. 
 
The hairs on the abdominal region of anesthetized animals will be cut close 
to the skin with scissors while the animals are in a supine position on the operating table 
with their paws and tail properly grounded and secured with adhesive tape. Antisepsis 
of the abdominal region will be performed using chlorhexidine suspended in an aqueous 
vehicle. 
 
A fenestrated sterile surgical field will be placed in the abdominal region of 
the animal, and a median incision of approximately 5 cm in length will be generated in 
the abdominal wall using a disposable scalpel (blade number fifteen). 
 
Initially, the cecum will be identified and exposed together with the terminal 
ileum. Subsequently, in both groups, the small intestine will be sectioned transversely in 
regions that are 3 and 5 cm distant from the ileocecal transition. In addition, a 2-cm ileal 
segment will be resected for the histological study. 
 
In the TG animals, the ileum will be resectioned transversely at a distance of 
15 cm from the ileocecal transition to separate an ileal segment of 10 cm, which will be 
wrapped in gauze that has been previously moistened with heated 0.9% sodium chloride 
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solution (Figure 1A). This procedure will be followed by anastomosis of the remaining 
ileal segments to restore the continuity of the digestive tract. Subsequently, the jejunum 
will be sectioned in two places (a distance of 5 and 6 cm from the duodenum-jejunum 
transition), and a 1-cm segment of the jejunum will be resected to perform anatomical 
and pathological studies (Figure 1A). The segment of distal ileum will be interposed to 
the previously separated segments of the sectioned jejunum in a isoperistaltic position 
via entero-enteroanastomosis (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A Figure 1B 
 
 
Figure 1A - Schematic of the regions of the intestinal section and the isolated ileal 
segment (filled in black) implemented in the procedure. 
 
Figure 1b - Diagram showing the previously anastomosed distal ileum and 
transposed anastomosed ileal segment (filled in black) in the initial segments of the 
jejunum. 
                   In SG animals, the intestine will be sectioned transversely in regions located 
at a distance of 15 cm from the ileocecal transition and 5 and 6 cm from the duodenal-
jejunal transition, following the making of primary intestinal anastomosis, without 
transposition, after the same jejunal and ileal resections for study similar to the TG. 
                 All   of   the   intestinal   anastomoses   will   be   termino-terminal   and  
performed at six separate points using a 7-0 polypropylene thread that is pre-assembled 
in a cylindrical needle. 
After the final revision and completion of the surgical procedure, the 
animals will be hydrated via an intraperitoneal injection of 1.0 mL of crystalloid 
solution (0.9% saline solution) for every 300 g of body weight at 36ºC. 
 
Synthesis of the abdominal wall will be performed by continuous suturing in 
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a monobloc of the parietal peritoneum, the muscular layer and the aponeurosis using a 
4-0 polyglactin thread that is pre-mounted in a cylindrical needle. A continuous suture 
with inverted points will be generated in the skin using a 4-0 polyglactin thread that is 
pre-mounted in a cylindrical needle. 
Postoperative treatment 
 
The animals will be kept warm and observed until complete recovery from 
the anesthesia. Subsequently, they will be placed in individual cages and transported to 
the mouse facility in the same laboratory under the same pre-operative environmental 
conditions. 
 
Prior to the recovery from anesthesia, analgesia will be applied by gavage 
with 0.5 mL of a solution containing 3 g of dipyrone dissolved in 1 mL of water. Water 
will be reintroduced ad libitum water immediately after recovery from the anesthesia. 
During the first 72 hours after surgery, the rats will be maintained with 1 g dipyrone 
diluted in 100 mL of water. They will be permitted access to the diet for 12 hours after 
completion of the surgery. 
 
The animals will be evaluated and monitored until the 8
th
 week after 
surgery, i.e., the 28
th
 week of life (S28), which is equivalent to a five-year postoperative 
period in humans.
171
 
 
Euthanasia 
 
In 28-week-old animals, the same fasting, anesthetic, weighing and blood 
sampling procedures for laboratory tests will be performed followed by decapitation, 
according to guidelines of the Sociedade Brasileira de Ciência de Animais de 
Laboratório/Colégio Brasileiro de Experimentação Animal – SBCAL-COBEA. 
                   Body Composition 
 
Following euthanasia, the fat deposits in the periepididymal and 
retroperitoneal regions will be collected and weighed using a precision scale. This 
procedure will be conducted for all of the animals in each group to quantify the amount 
of adiposity. 
 
Collection of Pancreatic Tissue 
 
Following euthanasia, the pancreas will be collected from animals in each 
groups for the pathological and immunohistochemical studies. The organ will be 
resected in a monobloc near the large gastric curvature and the splenic region. 
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Collection of Intestinal Tissue 
 
Upon completion of the surgery in SG and TG, tissue will be collected for 
the initial histological evaluation from the following regions: 
 
- distal ileal segment - I 1 (ileum, at time 1);  
 
- proximal jejunal segment - J 1 (jejunum, at time 1).  
 
Following euthanasia, the following intestinal tissues will be collected in all 
of the groups for a second analysis of the structural morphology of the intestine and the 
intestinal cells that produce incretin hormones (L cells) as well as their possible long-
term modifications: 
 
- ileal segment, distal to the ileoileal anastomosis - I 2 (ileum, at time 2). 
 
- jejunal segment, distal to the ileojejunal in TG and jejunojejunal in SG and about 7 cm 
from the duodenaljejunal transition in GC1 and GC2 - J 2 (jejunum, at time 2); 
 
- median ileal segment transposed in the TG and its corresponding segment in the SG, 8 
cm from the ileocecal transition - T 2 (transposed segment, at time 2). 
 
 
Collection of Liver Tissue 
 
Following euthanasia, the liver from each animal will be resected, weighed 
on a precision scale and subjected to a histopathological analysis. 
 
                   Histology - Optical Microscopy and Immunohistochemistry 
30 
Pancreatic tissue: 
 
The pancreas of each animal will be dried in a monobloc for an evaluation 
using optical microscopy. The tissue will be properly positioned in a cassette, fixed in 
10% buffered formaldehyde for 12 hours and then processed for paraffin embedding. 
Histological sections will be obtained using a Minot-type microtome set to a thickness 
of 5 m and placed along the long axis of the tissue on slides that have been previously 
treated with 5% silane. 
 
The slides will be stained with hematoxylin-eosin for the morphometric 
analysis of the pancreas. Specific antibodies will be used for immunohistochemistry: 
- polyclonal antibody H-86:SC-9168, which marks insulin-producing 
cells (Santa Cruz Biotechnology). 
 
- monoclonal anti-rat antibody to assess the proliferation marker Ki67, 
clone MIB-5, code: M7248-1, DAKO. 
 
Intestinal tissue: 
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The removed intestinal segments from each animal will be opened in the 
contra-mesenteric region and carefully washed with saline solution for evaluation by 
light microscopy. Next. they will be arranged on a piece of filter paper with the 
maintenance of direct contact with the serosa and with the mucosal face directed 
upward. The segments will then be placed in a wide mouth jar in 10% buffered 
formaldehyde at 10 times the tissue volume for 12 hours. During this time, the mucosal 
face will remain in direct contact with the solution. Subsequently, processing for 
paraffin embedding will be performed. Histological sections will be obtained using a 
Minot-type microtome set to a thickness of 5 m and placed on slides (using the inside 
perimeter of the region) that have been previously treated with 5% silane. 
 
The slides will be stained with hematoxylin-eosin for morphometric 
analyses of the intestine in all of the resected segments. Specific antibodies will be used 
for the immunohistochemistry study: 
- anti-GLP-1 sc7782 antibody, clone C-17, 1:500 dilution (Santa Cruz Biotechnology). 
- anti-rat monoclonal antibody to assess the marker of cell proliferation Ki67, MIB-5 
clone, code: M7248-1, DAKO. 
 
Liver tissue: 
 
After weighing the liver of each animal, it will be macroscopically sectioned 
along the long axis of the organ with the hilum side facing downward. Two fragments 
measuring 1.5x1.5x0.5 cm each will be obtained from each liver lobe and fixed in 10% 
formalin for 12 hours. Next, both fragments will be processed in a single paraffin block. 
Histological sections will be obtained using a Minot-type microtome set at a thickness 
of 5 m and placed on slides that have been previously treated with 5% silane. 
 
Standard techniques will be used for hematoxylin-eosin and Masson 
trichrome staining of the slides for the histopathological analysis and staging. 
 
 
Immunohistochemistry protocol: 
 
The slides containing the pancreas fragments will be double-stained using 
the EnVision G/2 Doublestain System (Rb/Mo (DAB+/Permanent Red), code: K5361-
1, Dako). The results will be visualized using peroxidase (HRP) and alkaline 
phosphatase (AP) with DAB+ and Permanent Red as the chromogen, respectively. 
 
The slides will be assessed using immunohistochemistry by double-staining 
with antigen using the LSAB Kit. The results will be visualized using peroxidase (HRP) 
with DAB+ as the chromogen. 
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The following protocol will be used for the histological sections: 
 
a) Dewaxing: the blades will be left in an incubator at 60°C for 12 hours to 
obtain optimal tissue adhesion and then dewaxed in three xylene baths of five minutes 
each at room temperature; 
 
b) Hydration: the blades will be submerged twice in absolute ethanol for 
five minutes and washed with running water for two minutes for hydration; 
 
c) Antigen Retrieval: the slides will be placed in a sodium citrate solution of 
10 mM, pH 6.0 for 30 minutes in a steam pan (95ºC), allowed to cool to room 
temperature for 20 minutes and washed in 0.05 M PBS (phosphate- 
buffered saline), pH 7.4 four times for three minutes each; 
 
d) Blocking of Endogenous Peroxidase: the slides will be incubated with 3% 
hydrogen peroxide four times for five minutes each and then washed with running water 
and PBS, pH 7.4 three times for three minutes each; 
 
e) Blocking of Nonspecific Sites: the slides will be incubated with PBS, pH 
7.4 + 1% BSA (bovine serum albumin) for 30 minutes at room temperature; 
 
f) Primary Antibody: histological sections of each slide will be incubated 
with the primary antibody SC-9168 to mark the insulin-producing cells in pancreatic 
tissue and SC-7782 to mark L cells in intestinal tissue. The antibodies will be diluted in 
PBS + 1% BSA according to the titration recommended by the supplier, and the slides 
will be incubated in a moist chamber at 4°C for 16-18 hours and then washed with PBS, 
pH 7.4 3 times; 
 
g) Secondary Antibody: the sections will be incubated with the secondary 
antibody conjugated to biotin provided in the DAKO EnVision Kit for pancreatic tissue 
and in the Dako LSAB Kit for intestinal tissue. The incubation will be performed for 30 
minutes at room temperature in a moist chamber. Next, the slides will be washed three 
times with PBS, pH 7.4 and then incubated with the amplification solution (HRP-
conjugated streptavidin) provided in the Dako kit for 30 minutes followed by three 
washes with PBS, pH 7.4; 
 
h) Visualization: the slides will be incubated with 3,3' diaminobenzidine 
solution (liquid DAB) for 15 minutes and then washed with distilled water; 
 
i) Blocking of Double Staining: the pancreatic and intestinal tissue sections 
will be incubated with the double staining blocking solution for three minutes and then 
washed with PBS. The sections will then be incubated with the endogenous enzyme 
blocking solution provided in the Dako EnVision Kit and washed with PBS; 
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j)    Second    Primary    Antibody:    the    histological    sections    will    be incubated    
with    the    second    primary    antibody,    M7248-1,    to    assess    cell proliferation.  
The  antibody  will  be  diluted  in  PBS  +  1%  BSA  using  the  titration recommended  
by  the  supplier,  and  the  slides  will  be  incubated  in  a  moist chamber at 4°C for 
16-18 hours and then washed three times with PBS, pH 7.4; k)   Second   Secondary    
 
                  Antibody:   sections   of   both   pancreatic   and intestinal tissues will be 
incubated with the second secondary antibody conjugated provided in the Dako 
EnVision Kit for 30 minutes at room temperature in a moist chamber. Following the 
incubation, the slides will be washed in PBS, pH 7.4 three times, incubated with the 
amplification solution (streptavidin conjugated to alkaline phosphatase) provided in the 
Dako kit for 30 minutes and then washed three times with PBS, pH 7.4; 
 
l) Visualization: the sections will be incubated with the Permanent Red 
chromogen solution for 20 minutes; 
 
m) Counterstaining: the sections will be washed under running water for 
five minutes and then counterstained with Harris hematoxylin for 20 seconds; 
 
n) Dehydration and Mounting: the slides will be washed with water for  
 
10 minutes and immersed in absolute ethanol four times and then in xylene three times. 
The slides will then be coverslipped using Etellan® mounting medium and visualized.  
 
Histological sections of the pancreas and ileum from one animal in the 
control group will be used as an internal positive control in the immunohistochemical 
studies, as appropriate. The omission of the respective primary antibodies during the 
histological procedures will serve as a negative control. 
 
For the pancreatic tissue, the appearance of a brown color will indicate 
positive staining using the DAB+ chromogen, and the presence of a red color will 
demonstrate positive staining with the Permanent Red chromogen. For the intestinal 
tissue, the presence of a brown color will indicate positive staining. Immunoexpression 
will be evaluated by image representation using a computerized system that consists of 
a light microscope (Carl Zeiss) adapted to a high-resolution camera (Carl Zeiss 
AxioCam MRc) and color video monitor (Samsung). The images will be obtained using 
the Carl Zeiss image analysis software AxioVision REL 4.2. 
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 Study Parameters 
 
 
Weight: Immediately after initiation of the light cycle, the weight of each 
animal from each of the four groups (TG, SG, GC1 and GC2) will be determined using 
a precision scale and recorded in grams (P1, P2, P3, .., P32).  
Feed consumption: All of the animals will receive a known quantity of feed 
that is sufficient for their daily needs. The remaining feed will be weighed using an 
appropriate scale three times a week, and the difference between the amount of feed 
supplied and that remaining will be used to calculate the daily feed intake. 
 
Biochemical tests: The amounts of serum glucose (GLU), insulin (INS), 
triglycerides (TG), total cholesterol (COL) and its fractions (HDL and LDL), glucagon-
like peptide-1 (GLP-1), peptide C (PTC) and glycated hemoglobin (HBG) will be 
determined in all of the animals. These levels will be assessed at the beginning of the 
procedure (12 weeks of age), during surgery (20 weeks of age) and at the time of 
euthanasia (28 weeks of age), which will be denoted as times 1, 2 and 3, respectively. 
 
Insulin resistance: Insulin resistance (IR) will be calculated using the 
homeostasis model assessment of insulin resistance (HOMA-IR) indirect test, and this 
value will be calculated based on the product of serum insulin (mU/mL), glucose 
(mg/mL) and the constant 0.05551 divided by 22.5. This calculation will be performed 
for times 1, 2 and 3. 
 
Insulin tolerance test (ITT): ITT will be performed for all of the animals at 
the beginning of the experimental procedure and at the time of surgery and euthanasia 
(times 1, 2 and 3). The rate of glucose disappearance is calculated using the formula 
In2/t1/2, and the t1/2 of glucose is calculated based on the linear phase of decline in the 
plasma glucose concentration determined in the minimum regression curve using 
PRISMA software. 
 
Body fat: On the day of euthanasia, periepididymal and retroperitoneal fat 
deposits will be collected from all of the animals in each group and weighed on a 
precision scale. The adiposity index will be calculated based on the proportion while 
considering the body weight of each animal. 
 
Liver weight: On the day of euthanasia, the resected liver from each animal 
will be weighed using an appropriate scale, and the values will be recorded in grams. 
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Histopathological Analysis - Interpretations of the Optical Microscopy 
and Immunohistochemistry Results: 
 
Pancreatic tissue: 
35 
Hematoxylin-eosin-stained slides will be used for the morphometric analysis 
of the pancreas; the area comprising the islets of Langerhans and the number of islet 
cells will be determined. Double labeling via immunohistochemistry will be used to 
determine the number of insulin-producing and proliferating cells. 
 
Images of the histological sections of the pancreas will be scanned and 
analyzed using ImageJ software. The total pancreatic tissue will be measured in each 
rat; this represents all of the fields captured in an increase of 400 times the greatest cut 
diameter of tissue obtained. The islets will then be distinguished for counting and 
measurements of their area. A relationship will be established between the total area of 
the islets and the total area of the pancreatic tissue. The mean area of the islets and 
average number of islets will be determined. In each islet of Langerhans, the following 
cells will be counted: cells stained for insulin, unstained cells, proliferating cells and 
proliferating cells stained for insulin. A relative value among labeled, unlabeled, 
proliferating and labeled proliferating cells will be established. 
Intestinal tissue: 
 
By staining with hematoxylin-eosin, the intestinal mucosal cells will be 
examined by global microscopy to determine differences in the shape, structure, size 
and number of the cells. The number of villi and crypts will be counted, and the height 
of 10 villi and 10 crypts from each intestinal segment will be measured to establish a 
ratio. The total thickness of the wall will also be measured. 
 
Enteroendocrine cells related to the GLP-1 hormone (L cells) will be 
identified by immunohistochemistry and evaluated in relation to their structure, shape, 
size and number. Next, we will count and evaluate the general characteristics of the L 
cells. Subsequently, its density will be determined based on the ratio of the number of L 
cells to the area of the mucosal tissue (crypts and villi). Double labeling via 
immunohistochemistry will also be performed to count the number of L cells 
undergoing proliferation. 
Liver tissue: 
 
Histological sections stained with hematoxylin-eosin and Masson's 
trichrome will be analyzed according to the international modified parameters of 
Kleiner and Brunt, which are used to stage the degree of nonalcoholic fatty liver 
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disease, according to the NAS - nonalcoholic fatty liver disease (NAFLD) activity score 
of the Pathology Committee of the Clinical Research Network.
172,177
 
 
Macrovesicular steatosis will be classified as follows: grade 1 - a mild 
attack with less than 33% of the hepatocytes affected; grade 2 - a moderate with 33% to 
66% of the hepatocytes affected; grade 3 - a severe with more than 66% of the 
hepatocytes affected. 
 
Microvesicular steatosis will be classified as absent or present, and the 
associated localization in the acini will be recorded. 
 
Hepatocyte ballooning will be considered absent, occasional or frequent, 
and the location of this event will be recorded. 
 
Lobular inflammatory activity will be classified as absent, mild (1-2 foci, 
20-fold magnification), moderate (3-4 foci, 20-fold magnification) and severe (>4 foci, 
20-fold magnification). 
 
The portal inflammatory infiltrate will be classified as absent, mild, 
moderate and intense based on the phenotypic characterization. In the absence of 
lobular activity, the result will be considered only as steatosis. 
 
The degree of fibrosis will be classified as follows: absent, grade 1 - 
fibrosis limited to the perivenular area; grade 2 - perivenular fibrosis with minimal 
septation; grade 3 - alterations of the lobular architecture with septation and incipient 
nodular formation; and grade 4 - cirrhosis. 
 
A diagnosis of nonalcoholic steatohepatitis will be established according to 
the American Association for the Study of Liver Diseases, and it will require the 
presence of steatosis, a mixed infiltrate and/or hepatocellular ballooning and/or 
pericellular fibrosis in the center-lobular area.
178-179
 
 
Statistical Analysis 
 
The variables will be summarized per study group according to the relevant 
descriptive statistics: absolute frequency (n) and relative (%) or mean, standard 
deviation (SD), median and minimum and maximum values. The data will be analyzed 
using parametric or nonparametric tests depending on the observed distribution. 
 
For a normal distribution of the data, analysis of variance with two fixed 
factors will be applied: groups (four levels: TG, SG, CG1 and CG2); evaluation (three 
levels: week 12 (W12), week 20 (W20) and week 28 (W28)). For variables that are 
measured weekly, the analysis will comprise 16 levels according to the week (week 1 
(W12); week 2 (W13), week 28 (W16)). In all of the other instances, the Mann-Whitney 
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test will be applied to compare techniques within each assessment, and the Friedman 
test will be used for related samples to compare assessments within each technique. The 
presence of an association between qualitative variables will be evaluated using the chi-
square or Fisher‟s exact test. The significance level will be established as 0.05 (α=5%), 
and descriptive levels (p) below this value will be considered significant. 
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